Kenneth Ataga, MBBS
Kenneth Ataga, MBBS, principal investigator of the SUSTAIN trial and director of the Comprehensive Sickle Cell Program in the University of North Carolina School of Medicine.

Results from an international, multicenter phase 2 clinical trial led by Dr. Kenneth Ataga were published online by the New England Journal of Medicine on December 3 and were presented December 4 at the annual meeting of the American Society of Hematology in San Diego. The trial found that an investigational compound called SeIG1 dramatically reduces sickle cell pain crises.